Drugs
Immunex and Genentech have reaffirmed their intention to move forward with their collaborative preclinical study of TRAIL/Apo2L in cancer research. Published experiments, including in vitro and in vivo preclinical models, have demonstrated that TRAIL/Apo2L has the ability to kill a broad cross-section of human tumor cell types without
Drugs
CuraGen Corporation and Genentech Inc. have renewed their drug research collaboration for a minimum of two and a half years. The collaboration, established in 1997, involves the application of CuraGen's genomic technologies and disease expertise to advance the discovery of novel protein therapeutics and antibodies. CuraGen will receive
Drugs
Diversa Corp. and Aventis Animal Nutrition S.A., a subsidiary of Aventis S.A., announced an extension of their research agreement to develop a biocatalytic process for manufacturing a key Aventis product for animal nutrition. This extension will provide additional research funding to Diversa, furthering their collaborative efforts to optimize
Drugs
Genzyme General has terminated its definitive agreement to acquire Cell Genesys, a decision that follows the latter's board of directors withdrawing its recommendation for the proposed acquisition. The Termination fee for Cell Genesys is $15 million. This development stems from the significant increase in the value of Cell
Drugs
Genentech, a leading biotechnology company, and XOMA Ltd. have initiated a Phase III clinical trial for an investigational monoclonal antibody, anti-CD11a (hu1124), to treat moderate-to-severe plaque psoriasis. This decision follows promising Phase II trial results, which indicate the potential for anti-CD11a to prevent T-cell activation and migration, key contributors to
Drugs
Corixa Corporation, a biotechnology company based in Seattle, Washington, and Zenyaku Kogyo Co., Ltd., a Japanese pharmaceutical company, have entered into a multi-year license, research and development agreement for the psoriasis immunotherapeutic product, PVAC. The agreement grants Zenyaku Kogyo exclusive rights to PVAC in Japan, while Corixa and Genesis Research
Drugs
CytoTherapeutics, Inc. announced a net loss of $1,840,000 for the second quarter ended June 30, 1999, compared to a net loss of $4,048,000 in the second quarter of 1998. The company's revenues from collaborative arrangements increased by 32% to $2,521,000, driven by
Pharmaceutical industry
Genentech, a leading biotechnology company, and Alkermes, a developer of sophisticated drug delivery technologies, have announced plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Nutropin Depot, a sustained release formulation of recombinant human growth hormone (rhGH). The decision was based
Pharmaceutical industry
The Immune Response Corporation, a biopharmaceutical company based in Carlsbad, California, has announced the receipt of $5 million from Agouron Pharmaceuticals, Inc. in conjunction with their collaboration to develop and commercialize REMUNE, an immune-based therapy for the treatment of HIV infection. This payment consists of $3 million for research and
Biotechnology industries
Genentech, Inc., a leading biotechnology company, and Roche Holdings, Inc. have revised their merger agreement, announced in May 1995, to change the form of the transaction. The new agreement extends for four years Roche's option to purchase Genentech's outstanding common stock at escalating prices, up to
Biotechnology industries
Martek Biosciences Corp. has made a significant financial move by selling 915,816 shares of its common stock and warrants to purchase 320,215 shares of its common stock to institutional investors. This transaction, valued at $9.1 million, will provide the company with additional resources to commercialize its innovative
Pharmaceutical industry
Researchers at The Rockefeller University have made a significant breakthrough in understanding the cause and potential treatment of psoriasis, a debilitating skin condition affecting approximately 2% of the population, or between 2.5 and 5 million people in the United States. An open-label, Phase I/II clinical trial conducted under
